12:00 AM
Feb 07, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

BF-200 ALA regulatory update

Biofrontera said CHMP recommended approval of an MAA for BF-200 ALA to treat actinic keratosis under the provision that satisfactory responses are given to the agency's Day...

Read the full 115 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >